Denmark’s Medicines Agency has approved Allocetra cell therapy from Israel’s Enlivex (see here previously) for Phase II clinical trials on patients with osteoarthritis in the knee. 40% of men and 47% of women develop knee osteoarthritis in their lifetimes. Allocetra … Continue reading →

Allocetra from Israel’s Enlivex (see here previously) saved many patients suffering from Covid-19 and sepsis. Clinical trials have now begun, using it to treat patients with advanced solid tumors. Allocetra reprograms immune system macrophages that cause cancer. https://www.jpost.com/jerusalem-report/article-713192 https://enlivex.com/investor-relations/#latest-news

On 2nd Mar, the JNF is hosting a webinar featuring Israeli and US innovations in the Life Sciences. It includes the Chief Scientific & Medical Officer Prof. Dror Mevorach of Israel’s Enlivex Therapeutics – developer of COVID-19 “cure” Allocetra.  Registration … Continue reading →

Allocetra from Israel’s Enlivex Therapeutics (reported here previously) has cured the majority of the 37 seriously and critically ill Covid-19 patients in its Phase 1b and 2 trials. 33 patients were discharged from hospital an average of under 6 days … Continue reading →

Israel’s Enlivex Therapeutics reported positive results in its clinical Covid-19 trial of its Allocetra treatment (reported here previously) Five seriously ill patients made complete recoveries, an average 8.5 days after receiving the treatment.at Jerusalem’s Hadassah hospital. https://www.jpost.com/israel-news/5-patients-leave-hadassah-coronavirus-free-after-clinical-trial-644071 https://www.calcalistech.com/ctech/articles/0,7340,L-3852110,00.html

As reported previously, (see here) the Allocetra treatment from Israel’s Enlivex cures patients suffering severe sepsis. Allocetra is now being offered to governments for the thousands of coronavirus patients suffering sepsis-induced organ failure due to overactive immune responses. https://www.jpost.com/HEALTH-SCIENCE/Israeli-company-ready-to-assist-coronavirus-victims-with-novel-drug-617777

As reported previously (see here) Israel’s Enlivex Therapeutics has developed Allocetra which rebalances the immune system. Allocetra was given to six patients suffering from severe sepsis at Hadassah hospital in Jerusalem. All survived. http://www.xinhuanet.com/english/2019-11/04/c_138528152.htm

I reported previously (see here) on Jerusalem-based immunotherapy company Enlivex Therapeutics. Enlivex has merged with Tel Aviv-headquartered Bioblast (see here), which is developing treatments for rare genetic diseases. https://www.calcalistech.com/ctech/articles/0,7340,L-3759270,00.html

In January I mentioned Apocell from Israeli biotech Enlivex, which prevents GVHD rejection of bone marrow transplants. Now, the treatment has received US FDA “orphan” status due to its importance and lack of alternatives for treating the unwanted autoimmune response. … Continue reading →